Literature DB >> 9748633

Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs.

R J Reid1, P Benedetti, M A Bjornsti.   

Abstract

The budding yeast Saccharomyces cerevisiae has been exploited to investigate the cytotoxic mechanisms of drugs that target DNA topoisomerases. This model organism has been used to establish eukaryotic DNA topoisomerase I or II as the cellular target of specific antineoplastic agents, to define mutations in these enzymes that confer drug resistance and to elucidate the cellular factors that modulate cell sensitivity to DNA topoisomerase-targeted drugs. These findings have provided valuable insights into the critical activities of these enzymes and how perturbing their functions produces DNA damage and cell death.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748633     DOI: 10.1016/s0167-4781(98)00142-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

1.  Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.

Authors:  Maryam B Lustberg; Tanios Bekaii-Saab; Donn Young; Gregory Otterson; William Burak; Abbas Abbas; Barbara McCracken-Bussa; Mark E Lustberg; Miguel A Villalona-Calero
Journal:  J Thorac Oncol       Date:  2010-05       Impact factor: 15.609

2.  Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

Authors:  Arnab Ray Chaudhuri; Yoshitami Hashimoto; Raquel Herrador; Kai J Neelsen; Daniele Fachinetti; Rodrigo Bermejo; Andrea Cocito; Vincenzo Costanzo; Massimo Lopes
Journal:  Nat Struct Mol Biol       Date:  2012-03-04       Impact factor: 15.369

3.  CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage.

Authors:  R J Reid; P Fiorani; M Sugawara; M A Bjornsti
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Topoisomerase assays.

Authors:  John L Nitiss; Eroica Soans; Anna Rogojina; Aman Seth; Margarita Mishina
Journal:  Curr Protoc Pharmacol       Date:  2012-06

5.  Identification of a topoisomerase I mutant, scsA1, as an extragenic suppressor of a mutation in scaA(NBS1), the apparent homolog of human nibrin in Aspergillus nidulans.

Authors:  Marcia R Z Kress Fagundes; Larissa Fernandes; Marcela Savoldi; Steven D Harris; Maria H S Goldman; Gustavo H Goldman
Journal:  Genetics       Date:  2003-07       Impact factor: 4.562

6.  Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.

Authors:  Y Xu; J M Kolesar; L J Schaaf; R Drengler; W Duan; G Otterson; C Shapiro; J Kuhn; M A Villalona-Calero
Journal:  Cancer Chemother Pharmacol       Date:  2008-09-16       Impact factor: 3.333

7.  Camptothecin enhances the frequency of oligonucleotide-directed gene repair in mammalian cells by inducing DNA damage and activating homologous recombination.

Authors:  Luciana Ferrara; Eric B Kmiec
Journal:  Nucleic Acids Res       Date:  2004-10-05       Impact factor: 16.971

8.  Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.

Authors:  Murugesan K Gounder; Ahamed S Nazar; Ahamed Saleem; Pooja Pungaliya; Diptee Kulkarni; Richard Versace; Eric H Rubin
Journal:  Invest New Drugs       Date:  2007-10-18       Impact factor: 3.850

9.  Chromosome-scale genetic mapping using a set of 16 conditionally stable Saccharomyces cerevisiae chromosomes.

Authors:  Robert J D Reid; Ivana Sunjevaric; Warren P Voth; Samantha Ciccone; Wendy Du; Aileen E Olsen; David J Stillman; Rodney Rothstein
Journal:  Genetics       Date:  2008-10-01       Impact factor: 4.562

10.  Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.

Authors:  Marié van der Merwe; Mary-Ann Bjornsti
Journal:  J Biol Chem       Date:  2007-12-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.